292 patents
Utility
Engineered NK Cells
18 Jan 24
Provided herein, inter alia, are compositions including engineered NK cells and methods for preparing the same.
Srividya Swaminathan, Anil Kumar, Sung June Lee, Adeleh Taghi Khani, Chun-Wei Chen
Filed: 26 Oct 21
Utility
Use of Triplex CMV Vaccine in CAR T Cell Therapy
18 Jan 24
A method for treating a patient comprising: (a) providing a composition comprising a population of T cells expressing both a chimeric antigen receptor (CAR) and a T cell receptor specific for a cytomegalovirus (CMV) antigen; (b) administering the composition to the patient; and (c) administering to the patient a viral vector encoding: (i) CMV pp65 and (ii) a fusion protein comprising exon 4 of CMV protein IE1 (e4) and exon 5 of CMV protein IE2 (e5) either prior to or subsequent to administering the composition comprising a population of T cells to the patient is described.
Don J. Diamond, Xiuli Wang
Filed: 19 Jul 23
Utility
Lamp Detection of SARS-COV-2 In Saliva for the Rapid Diagnosis of COVID-19
18 Jan 24
Provided herein are, inter alia, kits and methods for the detection SARS-CoV-2 in COVID-19 patients.
Markus KALKUM, Sanjeet DADWAL
Filed: 18 Aug 21
Utility
CS1 Targeted Chimeric Antigen Receptor-modified T Cells
11 Jan 24
Chimeric antigen receptors for use in treating malignant melanoma and other cancers expressing CS1 are described.
Xiuli Wang, Stephen J. Forman
Filed: 10 Jul 23
Utility
Prevention or Treatment of Wasting Syndrome
11 Jan 24
Provided herein are, inter alia, KIAA0930 inhibitors, pharmaceutical compositions, and methods for treating and preventing wasting syndromes, such as cancer cachexia.
Keiichi Itakura, Takahiro Yamakawa
Filed: 10 Jul 23
Utility
Oligonucleotides Containing 2'-DEOXY-2'FLUORO-BETA-D-ARABINOSE Nucleic Acid (2'-FANA) for Treatment and Diagnosis of Retroviral Diseases
4 Jan 24
The disclosure relates to synthetic oligonucleotides that bind at least a portion of a dimerization initiation site (DIS) of a retrovirus genomic ribonucleic acid (RNA) molecule.
John J. ROSSI, Masad J. DAMHA, Veenu AISHWARYA, Mayumi TAKAHASHI, Haitang LI
Filed: 29 Jun 23
Utility
Compositions and Methods for G-protein-coupled Receptor 44 Detection
4 Jan 24
Disclosed herein, inter alia, are compounds and methods for G-protein-coupled receptor 44 detection.
Fouad Kandeel, Junfeng Li, Jiangling Peng
Filed: 23 Aug 21
Utility
Treatment of Canavan Disease
28 Dec 23
Disclosed herein are methods of treating Canavan disease in a subject through restoring ASPA enzymatic activities in the subject by expressing an exogenous functional ASPA gene in the brain of the subject.
Yanhong SHI, Lizhao FENG, Jianfei CHAO, Guihua SUN
Filed: 5 Apr 23
Utility
Hydrophobic Drugs In Organic Core High Density Lipoprotein (HDL) Nanoparticles
28 Dec 23
Disclosed herein are high-density lipoprotein-like nanoparticles (HDL-NP) having a soft material core (e.g., a lipid-conjugated inorganic core) associated with hydrophobic therapeutic agents.
Stephen E. Henrich, Jonathan S. Rink, Adam Y. Lin, C. Shad Thaxton, Leo I. Gordon, Sonbinh T. Nguyen, Steven T. Rosen, David Horne, Xu Hannah Zhang
Filed: 22 Oct 21
Utility
Conditional-sirnas and Uses Thereof In Treating Acute Myeloid Leukemia
21 Dec 23
Disclosed herein are conditional siRNAs activatable by CBFβ-MYH11 oncogenic gene and use thereof for treating conditions such as acute myeloid leukemia (AML).
Guido MARCUCCI, Ya-Huei KUO, Si-Ping HAN, Lisa SCHERER, William A. GODDARD, III, John ROSSI
Filed: 28 Mar 23
Utility
Targeted Chimeric Antigen Receptor Modified T Cells for Treatment of IL13RALPHA2 Positive Malignancies
21 Dec 23
Chimeric antigen receptors targeted to IL-13Ra2 are described.
Christine E. Brown, Xin Yang, Renate Starr, Wen-Chung Chang, Stephen J. Forman
Filed: 12 Mar 21
Utility
Nucleic Acids, Proteins, and Vaccines of SARS-COV-2
21 Dec 23
Provided herein are, inter alia, SARS-CoV-2 spike (S) proteins; nucleic acids and plasmids encoding the proteins; vaccines and pharmaceutical compositions comprising the proteins, nucleic acids, or plasmids; methods for treating or preventing COVID-19; and methods for increasing immunity or providing acquired immunity to SARS-CoV in a subject.
Larry W. Kwak, Soungchul Cha, Szymon Szymura
Filed: 11 Nov 21
Utility
Compositions and Uses of Psca Targeted Chimeric Antigen Receptor Modified Cells
21 Dec 23
Nucleic acid molecules encoding an IL-15 domain and a chimeric antigen receptor (CAR) that targets cells expressing prostate stem cell antigen are provided as well as polypeptides encoded thereby.
Jianhua Yu, Michael A. Caligiuri
Filed: 23 Nov 21
Utility
Composition and Methods for 3D Culture of Islet Cells
21 Dec 23
Provided herein, inter alia, are compositions and methods for culturing islet cells.
Keiko OMORI, Fouad KANDEEL, Meirigeng QI
Filed: 18 May 23
Utility
Mva Vaccine for Delivery of a UL128 Complex and Preventing CMV Infection
14 Dec 23
In one embodiment, an expression system for expressing a UL128 complex is provided herein.
Don J. DIAMOND, Felix WUSSOW
Filed: 13 Jun 23
Utility
Multivalent Meditopes, Meditope-binding Antibodies and Uses Thereof
7 Dec 23
Provided are methods for altering the distribution of a cell surface antigen.
John C. WILLIAMS
Filed: 14 Dec 22
Utility
Biomarkers for Cancer Immunotherapy Outcomes
7 Dec 23
Provided herein, inter alia, are improved methods and systems of determining immunotherapy response in subjects prior and during treatment.
Andrea BILD, Jason I. GRIFFITHS
Filed: 30 May 23
Utility
Vaccination of Hematopoietic Stem Cell Donors with Cytomegalovirus Triplex Composition
30 Nov 23
Disclosed is a method of treating or preventing a CMV infection in a recipient of a hematopoietic cell transplant (HCT).
Don J. DIAMOND, Corinna LA ROSA
Filed: 15 Oct 21
Utility
TARGETED CHIMERIC ANTIGEN RECEPTOR MODIFIED T CELLS FOR TREATMENT OF IL13Ralpha2 POSITIVE MALIGNANCIES
23 Nov 23
Chimeric antigen receptor molecules that include a variant IL-13.
Christine E. Brown, Lawrence Stern, Xin Yang, K. Christopher Garcia, Ignacio Moraga Gonzalez
Filed: 19 Jan 21
Utility
Dual-targeting Chimeric Antigen Receptor Modified T Cells Comprising IL-13 and Chlorotoxin for Cancer Treatment
23 Nov 23
Chimeric antigen receptors having a chlorotoxin domain and an IL-13 are described.
Christine E. Brown, Dongrui Wang, Michael Barish, Stephen J. Forman
Filed: 11 Mar 21